Iodide

Iodide

SCHEMBL4401423

I.N=C(Nc1ccc(O)cc1)c1cccs1

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.51
RAB9A P51151 8/20 0.51
KMT2A Q03164 7/20 0.51
MEN1 O00255 6/20 0.51
TDP1 Q9NUW8 3/20 0.51
SMN1; SMN2 Q16637 4/20 0.45
MAPT P10636 4/20 0.45
LMNA P02545 2/20 0.45
GFER P55789 1/20 0.45
HTT P42858 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
ALDH1A1 P00352 4/20 0.42
TP53 P04637 3/20 0.42
CASP3 P42574 1/20 0.42
CASP2 P42575 1/20 0.42
GAA P10253 2/20 0.41
KDM4E B2RXH2 1/20 0.41
CYP3A4 P08684 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4409789 0.98 NPC1 (0.53) NPC1RAB9AKMT2AMEN1TDP1
Iodide SCHEMBL6957865 0.93 NPC1 (0.58) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL9048452 0.91 NPC1 (0.60) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL6280367 0.84 RAB9A (0.53) NPC1RAB9AKMT2AMEN1TDP1
Iodide SCHEMBL5418758 0.83 NPC1 (0.50) NPC1RAB9AKMT2AMEN1TDP1
Iodide SCHEMBL4402644 0.82 SMN1; SMN2 (0.46) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL9037874 0.81 NPC1 (0.80) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL4628336 0.81 NPC1 (0.51) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL7215866 0.80 MEN1 (0.49) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL4715529 0.80 NPC1 (0.49) NPC1RAB9AKMT2AMEN1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576241-B2 Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them IPSEN PHARMA S.A.S. (FR) 2009-08-18 US disclosed
US-7473779-B2 Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-01-06 US disclosed
US-20060084667-A1 New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them IPSEN PHARMA S.A.S. (FR) 2006-04-20 US disclosed
US-20050261269-A1 New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261269-A1 New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them NOS2, NOS1, NOS3 NPC1 1286/4885RAB9A 959/4885KMT2A 3477/4885
US-20060084667-A1 New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them ADM2, NUP155, ABCG2 NPC1 905/4885RAB9A 1624/4885KMT2A 4301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.